Simulations Plus, Inc. · NASDAQ:SLP

Simulations Plus — Lonza and Simulations Plus PBPK Modeling Webinar 2023

51 slides from Simulations Plus's conference presentation, Apr 27, 2023

  1. Slide 1: PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development

    Slide 1: PBPK Modeling for Identifying and Mitigating Absorption Risks in Early Drug Development

    Enabling a Healthier World PBPK Mod e ling for Id e nt ifying and Mit igat ing Ab sorp t ion Risks in Early Drug De ve lop m e nt De anna Mud ie , Ph.D, Se nior Princ ip al Engine e r, Lonza Sm all Mole c ule s John DiBe lla, Pre sid e nt, SLP Division, Sim ulations Plus 27 Ap ril 20 23 Public

  2. Slide 2: Agenda

    Slide 2: Agenda

    Age nd a The State of PBPK Modeling Oral Absorption Risks and Mitigation Strate gie s Lonza PBPK Mode ling Se rvic e s Ove rvie w PBPK Case Studie s 27 April 20 23

  3. Slide 3: The State of PBPK Modeling

    Slide 3: The State of PBPK Modeling

    The State of PBPK Mod e ling 27 April 2023

  4. Slide 4: What Do We Mean When Describing PBPK Modeling?

    Slide 4: What Do We Mean When Describing PBPK Modeling?

    What Do We Me an Whe n De sc rib ing PBPK Mod e ling? • Physiologic ally base d pharm ac okine tic (PBPK) m od e ls re p re se nt anim als and hum ans virtually as a c olle c tion of organs and tissue s, e ac h de fine d by a syste m of m athe m atic al e q uations • PBPK m od e ls are d e ve lop e

  5. Slide 5: Evolving Relationship Between PBPK Modeling and Pharmaceutical R&D

    Slide 5: Evolving Relationship Between PBPK Modeling and Pharmaceutical R&D

    Evolving Re lationship Be twe e n PBPK Mod e ling and Pharm ac e utic al R&D Mode l “supporte d” (first que stions 20 ye ars ago): • Will m ode ling and sim ulation he lp? Mode l “base d” (que stions 5 ye ars ago): • How c an I m axim ize the value of m ode ling and sim ulation in m y de ve lopm e n

  6. Slide 6: PBPK Modeling to Support Regulatory Interactions: The Push

    Slide 6: PBPK Modeling to Support Regulatory Interactions: The Push

    PBPK Mod e ling to Sup p ort Re gulatory Inte rac tions: The Push! 20 18 20 18 20 20 20 20 https:/ / www.fda.gov/ me dia http s:/ / www.e ma.e uropa.e u/ e n/ doc ume nt https:/ / www.fda.gov/ me dia https:/ / www.pmda.go.jp/ file s/ / 10 14 69/ download s/ sc ie ntific -guide line / guid e line -re

  7. Slide 7: PBPK Modeling Submissions to the FDA

    Slide 7: PBPK Modeling Submissions to the FDA

    PBPK Mod e ling Sub m issions to the FDA Zhang e t al. J Clin Pharm 20 20 Wu e t al. AAPS J 20 21 27 April 20 23 Public

  8. Slide 8: Examples of Approved Drugs Supported By PBPK Modeling

    Slide 8: Examples of Approved Drugs Supported By PBPK Modeling

    Exam p le s of Ap p rove d Drugs Sup p orte d By PBPK Mod e ling pH-dependent DDI drug product specifications / pH - metabolic DDI dependent DDIs pH-dependent DDI transporter DDI pH-dependent DDI drug product specifications transporter DDI drug product specifications drug product specifications pedi

  9. Slide 9: Common PBPK Modeling Industrial Applications

    Slide 9: Common PBPK Modeling Industrial Applications

    Com m on PBPK Mod e ling Ind ustrial Ap p lic ations FIH dose se le c tion and c linic al Support for optim al form ulation Pre dic tions of DDI liability; DDI study de sign de ve lopm e nt plans base d on se le c tion base d on pre c linic al support and biowaive r plans pre c linic al data data De

  10. Slide 10: PBPK Modeling to Support FIH Exposure Predictions

    Slide 10: PBPK Modeling to Support FIH Exposure Predictions

    PBPK Mod e ling to Sup p ort FIH Exp osure Pre d ic tions: in Vitro-in Vivo Extrap olation (IVIVE) Cole e t al., 20 0 8 – Asian ISSX Me e ting Jone s e t al. 20 11. Clin. Pharm ac okine t. 50 (5): 331 Mille r e t al., (20 19) Clin Pharm ac okine t 58(6):727-74 6 27 April 20 23 Public

  11. Slide 11: Pharmaceutical Risk Assessment Strategy: Proposed by Roche in 2006

    Slide 11: Pharmaceutical Risk Assessment Strategy: Proposed by Roche in 2006

    Pharm ac e utic al Risk Asse ssm e nt Strate gy: Prop ose d b y Roc he in 20 0 6 Ke y take aways: • Re le vant form ulation de ve lopm e nt ac tivitie s should inc lude additional PBPK m ode ling ste p • Me aningful de ve lopm e nt re sourc e s c an be assigne d one ye ar be fore the first-in-hum an

  12. Slide 12: Pharmaceutical Risk Assessment Strategy: BCS Class II Case Study

    Slide 12: Pharmaceutical Risk Assessment Strategy: BCS Class II Case Study

    Pharm ac e utic al Risk Asse ssm e nt Strate gy: BCS Class II Case Stud y • BCS asse ssm e nt sugge ste d solubility e nhanc e m e nt would im prove oral bioavailability • Me c hanistic Param e te r Se nsitivity Analysis was pe rform e d to asse ss the im pac t of c hange s to partic le size and sol

  13. Slide 13: Pharmaceutical Risk Assessment Strategy: BCS Class II Case Study

    Slide 13: Pharmaceutical Risk Assessment Strategy: BCS Class II Case Study

    Pharm ac e utic al Risk Asse ssm e nt Strate gy: BCS Class II Case Stud y • Base d up on the p re d ic tions from GastroPlus®, in vivo d og PK stud ie s we re p e rform e d using two d iffe re nt form ulations • “Be st” form ulation: Cre m ophor ve hic le solution • “Worst” form ulation: Pure drug s

  14. Slide 14: Formulation Screening and Dissolution Method Selection in Preclinical Species

    Slide 14: Formulation Screening and Dissolution Method Selection in Preclinical Species

    Form ulation Sc re e ning and Dissolution Me thod Se le c tion in Pre c linic al Sp e c ie s Base line m od e l d e ve lop m e nt for lac id ip ine : rat and d og IV and PO susp e nsion stud ie s 27 April 20 23 Public

  15. Slide 15: Formulation Screening and Dissolution Method Selection in Preclinical Species

    Slide 15: Formulation Screening and Dissolution Method Selection in Preclinical Species

    Form ulation Sc re e ning and Dissolution Me thod Se le c tion in Pre c linic al Sp e c ie s Dog PK d ata afte r PO ad m inistration of d iffe re nt tab le t form ulations was use d to se le c t the b iop re d ic tive in vitro d issolution e xp e rim e nt Wu e t al. RSC Adv. (20 15) 5;1984 4 27 Apri

  16. Slide 16: Formulation Screening and Dissolution Method Selection in Preclinical Species

    Slide 16: Formulation Screening and Dissolution Method Selection in Preclinical Species

    Form ulation Sc re e ning and Dissolution Me thod Se le c tion in Pre c linic al Sp e c ie s • Dog ACATΪ and PK m od e l translate d to hum an • Data from biopre dic tive in vitro d issolution e xp e rim e nt use d to suc c e ssfully p re d ic t hum an PK Wu e t al. RSC Adv. (20 15) 5;1984 4 27 Apri

  17. Slide 17: The GastroPlus PBPK Platform Is Validated Throughout Your Drug Product's Lifecycle

    Slide 17: The GastroPlus PBPK Platform Is Validated Throughout Your Drug Product's Lifecycle

    The GastroPlus® PBPK Platform Is Valid ate d Throughout Your Drug Prod uc t’s Life c yc le (10 0 0 + p e e r-re vie we d journal art ic le s re fe re nc e Gast roPlus® ap p lic at ions) LEAD SELECTION FIRST-IN-HUMAN FOOD EFFECTS pH-DEPENDENT DDI METABOLIC DDI BIOEQUIVALENCE Naga et al. (2022) Miller

  18. Slide 18: Professional Development: What a Great Time to be a PBPK Modeler

    Slide 18: Professional Development: What a Great Time to be a PBPK Modeler

    Profe ssional De ve lop m e nt: What a Gre at Tim e to b e a PBPK Mod e le r Job Postings 139 127 67 53 42 NOV-18 NOV-19 NOV-20 NOV-21 NOV-22 MAY-19 MAY-20 MAY-21 MAY-22 FEB-19 AUG-19 FEB-20 AUG-20 FEB-21 AUG-21 FEB-22 AUG-22 27 April 20 23 Public

  19. Slide 19: PBPK Modeling Saves Resources in R&D and Regulatory Interactions

    Slide 19: PBPK Modeling Saves Resources in R&D and Regulatory Interactions

    PBPK Mod e ling Save s Re sourc e s in R&D and Re gulatory Inte rac tions 1 2 3 4 5 6 Prioritize and Inte grate data to Elim inate Im prove Re duc e Im prove patient make better tell a compelling unnecessary produc tivity to be regulatory lives investments story animal/human the first to burden stud

  20. Slide 20: Oral Absorption Risks and Mitigation Strategies

    Slide 20: Oral Absorption Risks and Mitigation Strategies

    Oral Ab sorp tion Risks and Mitigation Strate gie s 27 April 2023

  21. Slide 21: Solubility and Permeability are Key Underlying Mechanisms of Poor Oral Absorption

    Slide 21: Solubility and Permeability are Key Underlying Mechanisms of Poor Oral Absorption

    Solub ility and Pe rm e ab ility are Ke y Und e rlying Me c hanism s of Poor Oral Ab sorp tion Increasing Solubility Increasing Permeability II I • Marke te d Prod uc ts – 30 % • Marke te d Prod uc ts – 35% • Cand id ate s – 6 0 -70 % • Cand id ate s – 5-10 % IV III • Marke te d Prod uc ts – 10 % •

  22. Slide 22: Solubility and Permeability Depend on Drug Physicochemical Properties and GI Physiology

    Slide 22: Solubility and Permeability Depend on Drug Physicochemical Properties and GI Physiology

    Solub ility and Pe rm e ab ility De p e nd on Drug Physic oc he m ic al Prop e rtie s and GI Physiology Drug Properties Physiological Properties Im age sourc e : daviddarling.info 27 April 20 23 Public

  23. Slide 23: Poor Solubility and Permeability Can Negatively Impact In Vivo Oral Absorption

    Slide 23: Poor Solubility and Permeability Can Negatively Impact In Vivo Oral Absorption

    Poor Solub ility and Pe rm e ab ility c an Ne gative ly Im p ac t in Vivo Oral Ab sorp tion and Plasm a Exp osure Potential oral exposure risks With form/formulation mitigation Low bioavailability Drug c onc e ntration in blood Drug concentration in blood Without ARA/ Food Tim e With ARA/ Food ARA e

  24. Slide 24: Several Formulation Strategies Exist for Mitigating Poor Oral Absorption

    Slide 24: Several Formulation Strategies Exist for Mitigating Poor Oral Absorption

    Se ve ral Form ulation Strate gie s Exist for Mitigating Poor Oral Ab sorp tion Through Solub ility Enhanc e m e nt Solid-State Alteration: New crystalline compound Solvation, Complexation Form, Particle Size Polym orp hs Co-c rystals Co-solve nts Am orp hous solid d isp e rsions Salts Surfac tants

  25. Slide 25: Lonza PBPK Modeling Services

    Slide 25: Lonza PBPK Modeling Services

    Lonza PBPK Mod e ling Se rvic e s 27 April 2023

  26. Slide 26: Lonza PBPK Modeling Services Key Outputs for our Clients

    Slide 26: Lonza PBPK Modeling Services Key Outputs for our Clients

    Lonza PBPK Mod e ling Se rvic e s Ke y Outp uts for our Clie nts e .g. solubility, dissolution rate , pe rm e ability, food e ffe c t, pH- 1 Identify drug absorption risks de pe nde nt ARA e ffe c t e .g. salt, c oc rystal, am orphous solid dispe rsion Recommend absorption risk mitigation 2 strategi

  27. Slide 27: Lonza PBPK Modeling Services Key Components

    Slide 27: Lonza PBPK Modeling Services Key Components

    Lonza PBPK Mod e ling Se rvic e s Ke y Com p one nts Establishe d ADMET Pre dic tor ® and Vast e xpe rie nc e in API synthe sis, solubility An e xpansive se t of c ustom and off-the GastroPlus ® m ode ling and sim ulation e nhanc e m e nt, & form ulation she lf in-vitro pe rform anc e te sts softwar

  28. Slide 28: Lonza's Custom and Off-The-Shelf In Vitro Bioperformance Toolkit

    Slide 28: Lonza's Custom and Off-The-Shelf In Vitro Bioperformance Toolkit

    Lonza’s Custom and Off-The -She lf in Vitro Biop e rform anc e Toolkit Controlled transfer Amorphous solubility Dissolution Membrane flux dissolution • Am orp hous “solubility” • Dissolution rate • Im pac t of dissolve d spe c ie s on • Im p ac t of d ynam ic p H and diffusion transit on dissolution

  29. Slide 29: PBPK is Part of a Suite of Lonza Services that Streamline Drug Development

    Slide 29: PBPK is Part of a Suite of Lonza Services that Streamline Drug Development

    PBPK is Part of a Suite of Lonza Se rvic e s that Stre am line Drug De ve lop m e nt Drug Substance Preclinical Phase 2 Solid Form Services PBPK Modeling Services Particle Engineering Discovery Phase 1 IND Drug Product 27 April 20 23 Public

  30. Slide 30: Case Study – Early API Absorption Risk Assessment

    Slide 30: Case Study – Early API Absorption Risk Assessment

    Case Stud y – Early API Ab sorp tion Risk Asse ssm e nt 27 April 2023

  31. Slide 31: Early API Absorption Risk Assessment – Model Drug Posaconazole

    Slide 31: Early API Absorption Risk Assessment – Model Drug Posaconazole

    Early API Ab sorp tion Risk Asse ssm e nt – Mod e l Drug Posac onazole Posaconazole Inputs Outputs • API struc ture • Barrie rs to absorption • Crystalline solubility • Pe rc e nt dose absorbe d • Azole antifungal age nt • Am orphous In house solubility c alc ulator • Pote ntial • Brand nam e NOXAFI

  32. Slide 32: Posaconazole is a Lipophilic Weak Base with Solubility-Limited Absorption

    Slide 32: Posaconazole is a Lipophilic Weak Base with Solubility-Limited Absorption

    Posac onazole is a Lip op hilic We ak Base with Solub ility-Lim ite d Ab sorp tion De ve lopability Classific ation Syste m (DCS) In vitro solubility 10000 In vitro solubility (µg/ m L) 1000 100 Aqueous crystalline 10 solubility 6.7 mM bile salts 1 0.1 0 5 10 pH • pH-de pe nde nt solubility • Pote n

  33. Slide 33: Projected Percent Dose Absorbed in Fasted Humans is Low and Sensitive to Key Variables

    Slide 33: Projected Percent Dose Absorbed in Fasted Humans is Low and Sensitive to Key Variables

    Proje c te d Pe rc e nt Dose Ab sorb e d in Faste d Hum ans is Low and Se nsitive to Ke y Variab le s Parameter sensitivity analyses Gastric pH Pre c ipitation • Faste d hum an p hysiology 50 50 • IR tab le t Sim ulate d pe rc e nt absorbe d Sim ulate d pe rc e nt dose • 25 µm p artic le rad ius 40

  34. Slide 34: Posaconazole has Potential for pH-dependent DDIs with ARAs and Food-Drug Interactions

    Slide 34: Posaconazole has Potential for pH-dependent DDIs with ARAs and Food-Drug Interactions

    Posac onazole has Pote ntial for p H-d e p e nd e nt DDIs with ARAs and Food -Drug Inte rac tions Change in % ab sorb e d with ARA-ind uc e d Change in % absorbe d with fe d-induc e d p hysiology (10 0 -m g dose ) physiology (10 0 -m g dose ) With ac id re duc ing Faste d age nt (e .g. ARA) 40 1.7 X

  35. Slide 35: Evaluating Amorphous Form of Posaconazole to Mitigate Absorption Risks

    Slide 35: Evaluating Amorphous Form of Posaconazole to Mitigate Absorption Risks

    Evaluating Am orp hous Form of Posac onazole to Mitigate Ab sorp tion Risks • Me asure p osac onazole am orp hous solub ility pH 6.5 w/ 6.7 m M bile salts 100 30 X Solubility (µg/ m l) 10 1 Crystalline Amorphous Lonza c ustom in vitro solve nt shift UV assay 27 April 20 23 Public

  36. Slide 36: Projected Percent Dose Absorbed is Improved for Amorphous Form

    Slide 36: Projected Percent Dose Absorbed is Improved for Amorphous Form

    Proje c te d Pe rc e nt Dose Ab sorb e d is Im p rove d for Am orp hous Form Com p are d to Crystalline Fre e Base Fe d physiology im pac t –4 0 0 m g Gastric pH im pac t 100 1.2 X Parameter sensitivity analyses 100 1X Sim ulate d p e rc e nt ab sorb e d • Faste d hum an p hysiology Am orphous – 10

  37. Slide 37: Posaconazole Projected to be a Favorable ASD Candidate

    Slide 37: Posaconazole Projected to be a Favorable ASD Candidate

    Posac onazole Proje c te d to b e a Favorab le ASD Cand id ate 1E+2 1.7 CRYSTALLINE 1E+1 1.6 Aqueous Solubility (mg/mL) 1E+0 Group I: Crystallization Challenge Crystallization Tendency → 1.5 1E-1 Ibuprofen Tm/Tg (K/K) 1E-2 NANOCRYSTALS 1.4 Ketoconazole Group II: Centerline 1E-3 Indomethacin Ritonavi

  38. Slide 38: Posaconazole ASD Tablet Outperforms Crystalline Oral Suspension In Vitro

    Slide 38: Posaconazole ASD Tablet Outperforms Crystalline Oral Suspension In Vitro

    Posac onazole ASD Tab le t Outp e rform s Crystalline Oral Susp e nsion In Vitro Posaconazole ASD tablet In vitro dissolution test • Non-sink d ose c onc e ntration • 75/ 25 (w/ w) posac onazole / Eudragit ® L10 0 ASD granulate d with • 50 0  250 µg/ m l HPMCAS-H • p H 2  p H 6 .5 w/ 6 .7 m M b il

  39. Slide 39: Using PBPK Modeling for Preclinical Study Design & Risk Mitigation

    Slide 39: Using PBPK Modeling for Preclinical Study Design & Risk Mitigation

    Using PBPK Mod e ling for Pre c linic al Stud y De sign & Risk Mitigation Posaconazole Drug product formulations PBPK inputs Outputs ASD tab le t • API struc ture • Plasm a e xposure • Crystalline solubility • Am orphous e nhanc e m e nt NOXAFIL OS • Am orphous solubility • Se nsitivity to Lonza int

  40. Slide 40: ASD tablet projected to outperform crystalline suspension in fasted dogs

    Slide 40: ASD tablet projected to outperform crystalline suspension in fasted dogs

    ASD tab le t p roje c te d to outp e rform c rystalline susp e nsion in faste d d ogs PBPK model - GastroPlus® v9.6 100 Gastric p H =2 AUC 0 -Inf (µg ∙h m l-1) Am orphous • Faste d d og p hysiology 10 Crystalline • 10 0 m g single d ose • Bottom -up • No op tim ization 1 0 10 20 30 40 50 Pre c ipita

  41. Slide 41: ASD Tablet Achieves 2-Fold Improvement in AUC in Pentagastrin-Treated Dogs

    Slide 41: ASD Tablet Achieves 2-Fold Improvement in AUC in Pentagastrin-Treated Dogs

    ASD Tab le t Ac hie ve s 2-Fold Im p rove m e nt in AUC in Pe ntagastrin- Tre ate d Dogs in Line with PBPK Proje c tions 3.5 • 10 0 -m g (10 m g/ kg) d ose , n=6 3 • Crossove r study, 1-we e k washout Conc e ntration (µg/ m L) ASD tab le t 2.5 2 1.5 Crystalline susp e nsion 1 0.5 0 0 10 20 30 40 50

  42. Slide 42: Conclusions

    Slide 42: Conclusions

    Conc lusions Posac onazole Case St ud y Suc c e ssfully use d PBPK m od e ling and in house in vitro tools to: • Ide ntify p oor oral ab sorption of posac onazole Milligram s of API • Fore c ast am orp hous form as viab le strate gy to inc re ase ~1 we e k absorption and de c re ase se nsitivity to

  43. Slide 43: Case Study – Preclinical Study De-risking

    Slide 43: Case Study – Preclinical Study De-risking

    Case Stud y – Pre c linic al Stud y De -risking 27 April 2023

  44. Slide 44: Preclinical Study De-risking – Acalabrutinib Case Study

    Slide 44: Preclinical Study De-risking – Acalabrutinib Case Study

    Pre c linic al Stud y De -risking – Ac alab rutinib Case Stud y Gastric pH - Gastric pH – fasting on ARAs 10 1 Solubility (mg/ml) Bruton tyrosine kinase inhibitor indic ate d for onc ology 0.1 Plasm a AUC re duc e d by 4 3% whe n take n with PPI* Crystalline ac alabrutinib* 0.01 Patie nts m ust avoi

  45. Slide 45: Acalabrutinib ASD Tablet Developed to Overcome pH Effect

    Slide 45: Acalabrutinib ASD Tablet Developed to Overcome pH Effect

    Ac alab rutinib ASD Tab le t De ve lop e d to Ove rc om e p H Effe c t ASD tablet design In vivo study goals 50 / 50 ac alabrutinib/ HPMCAS-H ASD in IR table t Mitigate pH e ffe c t using ASD table t Matc h plasm a e xposure of faste d CALQUENCE® using ASD Good stability table t 60 % sm alle r than

  46. Slide 46: ASD Tablets Achieve Performance Goals In Vitro

    Slide 46: ASD Tablets Achieve Performance Goals In Vitro

    ASD Tab le ts Ac hie ve Pe rform anc e Goals In Vitro 10 0 mg d ose 46 (1 mg/ ml d ose c onc .) Gastric Compartment, pH 2 Intestinal Compartment 1000 600 Calque nc e c apsule Calque nc e c apsule Concentration (µg/mL) Concentration (µg/mL) 800 400 600 15-m in t 1/ 2 p H 2 or 6 ASD 400 ASD table t 20

  47. Slide 47: PBPK Predictions – Gain Confidence in Formulation Identified From In Vitro Testing

    Slide 47: PBPK Predictions – Gain Confidence in Formulation Identified From In Vitro Testing

    PBPK Pre d ic tions – Gain Confid e nc e in Form ulation Id e ntifie d From in Vitro Te sting 5,000 PBPK model - GastroPlus® v9.8 Acalabrutinib concentration (ng/ml) 4,000 ASD tablet, low pH • Faste d d og p hysiology 3,000 ASD tablet, high pH • 10 0 m g single d ose • Bottom -up Calquence capsule,

  48. Slide 48: In Vivo Data Matches Bottom-up PBPK Predictions for Successful Pre-Clinical Study

    Slide 48: In Vivo Data Matches Bottom-up PBPK Predictions for Successful Pre-Clinical Study

    In Vivo Data Matc he s Bottom – up PBPK Pre d ic tions for Suc c e ssful Pre -Clinic al Stud y Ove rnight fast, n = 6, c rossove r study, 100 mg dose 1 – wk washout AUC 0 -inf within 10 % for ASD tab le t at low and high pH 5,000 Acalabrutinib concentration (ng/ml) 4,000 ASD tablet, low pH* Good p r

  49. Slide 49: Overall Conclusions

    Slide 49: Overall Conclusions

    Ove rall Conc lusions Saving Time and Small Scale and Early Informed Money Ab sorp tion Risk Asse ssm e nts Root c ause analysis Re d uc e the ne e d for re form ulation and / or re p e ate d in vivo stud ie s • 1 we e k asse ssm e nt tim e • e .g. solub ility, d issolution, p e rm e ab ility lim it

  50. Slide 50: Acknowledgments

    Slide 50: Acknowledgments

    Ac knowle d gm e nts Aaron Stewart Josh Marsh David Vodak Jesus Rosales Adam Smith Henny Zijlstra Michael Morgen Christopher Craig David Lyon Kimberly Shepard Nishant Biswas Molly Adam 27 April 20 23 Public

  51. Slide 51: Q&As

    Slide 51: Q&As

    Q&As Contact us: small.molecules@lonza.com www.lonza.com 27 April 2023

Source: Internet Archive copy of simulations-plus.com

More decks from Simulations Plus, Inc.

All 167 Simulations Plus decks